Effect of Alendronate on Early Bone Loss of Renal Transplant Recipients
Abstract Introduction Renal transplant recipients (RTRs) are at risk of developing osteoporosis and osteopenia due to underlying renal osteodystrophy, hypophosphatemia, and immunosuppression. This process occurs more frequently in the first year after renal transplantation (RTX), resulting in eventu...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 2011-03, Vol.43 (2), p.565-567 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 567 |
|---|---|
| container_issue | 2 |
| container_start_page | 565 |
| container_title | Transplantation proceedings |
| container_volume | 43 |
| creator | Abediazar, S Nakhjavani, M.R |
| description | Abstract Introduction Renal transplant recipients (RTRs) are at risk of developing osteoporosis and osteopenia due to underlying renal osteodystrophy, hypophosphatemia, and immunosuppression. This process occurs more frequently in the first year after renal transplantation (RTX), resulting in eventual bone loss and fractures. The purpose of this study was to evaluate the effect of low-dose alendronate to prevent early bone loss after RTX. Patients and Methods We prospectively studied 43 successful RTR including 22 men and 21-women with a mean overall age of 39.16 ± 11.73 years, mean body mass index of 23.6 ± 3.73, and mean dialysis duration of 25.73 ± 17.67 months. We matched them based on age and sex: the alendronate-treated group received vitamin D (Vit D) during the study plus 30 mg alendronate weekly from 1 month after RTX. The control group only received Vit D. We measured serum calcium, phosphate, alkaline phosphatase, blood urea, creatinine, and intact parathyroid hormone (iPTH) at the pretransplant baseline and monthly thereafter as well as BMD of the lumbar spine, femur, and radius pretransplant baseline versus 3 and 6 months after RTX. Results At 6 month after RTX, the lumbar BMD in the alendronate group increased significantly from 0.819 ± 0.11 to 0.863 ± 0.14 ( P < .01), while it decreased in the control group from 0.897 ± 0.17 to 0.817 ± 0.16 ( P < .001). There was also a significant increase in radius BMD ( P < .001) and a nonsignificant increase in femoral BMD in the alendronate versus a significant decrease of femoral and radius BMD ( P < .001) in the control group at 6 months. Upon multivariate analysis, there was a significant correlation between alendronate and spine BMD ( r = .45, P < .001) but no linear regression between age, sex, BMI, dialysis duration of or iPTH with femoral, spine, or radius BMD changes at month 6. Conclusion Low-dose alendronate was significantly useful to mitigate fast bone loss and increase BMD immediately after RTX. |
| doi_str_mv | 10.1016/j.transproceed.2011.01.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_859054601</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0041134511000261</els_id><sourcerecordid>859054601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-ed15a9af0c63c819c78f6c435967be50c95481d8d00b4cad60aa21e713f084d53</originalsourceid><addsrcrecordid>eNqNkV-LEzEUxYMobnf1K8ggiE9T782_mfFBWNe6CgVB1-eQJjeQOp2pyVTotzez7aL4JFwISX655-Ycxl4iLBFQv9kup2SHvE-jI_JLDohLKMXVI7bAthE111w8ZgsAiTUKqS7YZc5bKHsuxVN2wVFKaDRfsNtVCOSmagzVdU-DT-NgJ6rGoVrZ1B-r9-NA1XrMeSa-0mD76u5evLfDVA5c3EcapvyMPQm2z_T8vF6x7x9Xdzef6vWX28831-vaKQFTTR6V7WwAp4VrsXNNG7STQnW62ZAC1ynZom89wEY66zVYy5EaFAFa6ZW4Yq9Pfcvvfx4oT2YXs6O-jEPjIZtWdaCkBizk2xPpUhk_UTD7FHc2HQ2CmX00W_O3j2b20UApPsu8OMscNrty9_D0wbgCvDoDNjvbh9LIxfyHkwhSqqZwH04cFVN-RUomu2KYIx9T8d34Mf7fPO_-aeP6OMSi_IOOlLfjIZVoskGTuQHzbU5-Dh6xhM41it--5auB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>859054601</pqid></control><display><type>article</type><title>Effect of Alendronate on Early Bone Loss of Renal Transplant Recipients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Abediazar, S ; Nakhjavani, M.R</creator><creatorcontrib>Abediazar, S ; Nakhjavani, M.R</creatorcontrib><description>Abstract Introduction Renal transplant recipients (RTRs) are at risk of developing osteoporosis and osteopenia due to underlying renal osteodystrophy, hypophosphatemia, and immunosuppression. This process occurs more frequently in the first year after renal transplantation (RTX), resulting in eventual bone loss and fractures. The purpose of this study was to evaluate the effect of low-dose alendronate to prevent early bone loss after RTX. Patients and Methods We prospectively studied 43 successful RTR including 22 men and 21-women with a mean overall age of 39.16 ± 11.73 years, mean body mass index of 23.6 ± 3.73, and mean dialysis duration of 25.73 ± 17.67 months. We matched them based on age and sex: the alendronate-treated group received vitamin D (Vit D) during the study plus 30 mg alendronate weekly from 1 month after RTX. The control group only received Vit D. We measured serum calcium, phosphate, alkaline phosphatase, blood urea, creatinine, and intact parathyroid hormone (iPTH) at the pretransplant baseline and monthly thereafter as well as BMD of the lumbar spine, femur, and radius pretransplant baseline versus 3 and 6 months after RTX. Results At 6 month after RTX, the lumbar BMD in the alendronate group increased significantly from 0.819 ± 0.11 to 0.863 ± 0.14 ( P < .01), while it decreased in the control group from 0.897 ± 0.17 to 0.817 ± 0.16 ( P < .001). There was also a significant increase in radius BMD ( P < .001) and a nonsignificant increase in femoral BMD in the alendronate versus a significant decrease of femoral and radius BMD ( P < .001) in the control group at 6 months. Upon multivariate analysis, there was a significant correlation between alendronate and spine BMD ( r = .45, P < .001) but no linear regression between age, sex, BMI, dialysis duration of or iPTH with femoral, spine, or radius BMD changes at month 6. Conclusion Low-dose alendronate was significantly useful to mitigate fast bone loss and increase BMD immediately after RTX.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2011.01.025</identifier><identifier>PMID: 21440762</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adult ; Alendronate - pharmacology ; Biological and medical sciences ; Body Mass Index ; Bone and Bones - drug effects ; Bone Density ; Bone Density Conservation Agents - pharmacology ; Bone Diseases - complications ; Densitometry - methods ; Diseases of the osteoarticular system ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Kidney Failure, Chronic - complications ; Kidney Transplantation - adverse effects ; Kidney Transplantation - methods ; Male ; Medical sciences ; Middle Aged ; Osteoporosis. Osteomalacia. Paget disease ; Prospective Studies ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tissue, organ and graft immunology</subject><ispartof>Transplantation proceedings, 2011-03, Vol.43 (2), p.565-567</ispartof><rights>2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-ed15a9af0c63c819c78f6c435967be50c95481d8d00b4cad60aa21e713f084d53</citedby><cites>FETCH-LOGICAL-c530t-ed15a9af0c63c819c78f6c435967be50c95481d8d00b4cad60aa21e713f084d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2011.01.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,777,781,786,787,3538,23912,23913,25122,27906,27907,45977</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24104457$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21440762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abediazar, S</creatorcontrib><creatorcontrib>Nakhjavani, M.R</creatorcontrib><title>Effect of Alendronate on Early Bone Loss of Renal Transplant Recipients</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Introduction Renal transplant recipients (RTRs) are at risk of developing osteoporosis and osteopenia due to underlying renal osteodystrophy, hypophosphatemia, and immunosuppression. This process occurs more frequently in the first year after renal transplantation (RTX), resulting in eventual bone loss and fractures. The purpose of this study was to evaluate the effect of low-dose alendronate to prevent early bone loss after RTX. Patients and Methods We prospectively studied 43 successful RTR including 22 men and 21-women with a mean overall age of 39.16 ± 11.73 years, mean body mass index of 23.6 ± 3.73, and mean dialysis duration of 25.73 ± 17.67 months. We matched them based on age and sex: the alendronate-treated group received vitamin D (Vit D) during the study plus 30 mg alendronate weekly from 1 month after RTX. The control group only received Vit D. We measured serum calcium, phosphate, alkaline phosphatase, blood urea, creatinine, and intact parathyroid hormone (iPTH) at the pretransplant baseline and monthly thereafter as well as BMD of the lumbar spine, femur, and radius pretransplant baseline versus 3 and 6 months after RTX. Results At 6 month after RTX, the lumbar BMD in the alendronate group increased significantly from 0.819 ± 0.11 to 0.863 ± 0.14 ( P < .01), while it decreased in the control group from 0.897 ± 0.17 to 0.817 ± 0.16 ( P < .001). There was also a significant increase in radius BMD ( P < .001) and a nonsignificant increase in femoral BMD in the alendronate versus a significant decrease of femoral and radius BMD ( P < .001) in the control group at 6 months. Upon multivariate analysis, there was a significant correlation between alendronate and spine BMD ( r = .45, P < .001) but no linear regression between age, sex, BMI, dialysis duration of or iPTH with femoral, spine, or radius BMD changes at month 6. Conclusion Low-dose alendronate was significantly useful to mitigate fast bone loss and increase BMD immediately after RTX.</description><subject>Adult</subject><subject>Alendronate - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Body Mass Index</subject><subject>Bone and Bones - drug effects</subject><subject>Bone Density</subject><subject>Bone Density Conservation Agents - pharmacology</subject><subject>Bone Diseases - complications</subject><subject>Densitometry - methods</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Kidney Transplantation - methods</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osteoporosis. Osteomalacia. Paget disease</subject><subject>Prospective Studies</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tissue, organ and graft immunology</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV-LEzEUxYMobnf1K8ggiE9T782_mfFBWNe6CgVB1-eQJjeQOp2pyVTotzez7aL4JFwISX655-Ycxl4iLBFQv9kup2SHvE-jI_JLDohLKMXVI7bAthE111w8ZgsAiTUKqS7YZc5bKHsuxVN2wVFKaDRfsNtVCOSmagzVdU-DT-NgJ6rGoVrZ1B-r9-NA1XrMeSa-0mD76u5evLfDVA5c3EcapvyMPQm2z_T8vF6x7x9Xdzef6vWX28831-vaKQFTTR6V7WwAp4VrsXNNG7STQnW62ZAC1ynZom89wEY66zVYy5EaFAFa6ZW4Yq9Pfcvvfx4oT2YXs6O-jEPjIZtWdaCkBizk2xPpUhk_UTD7FHc2HQ2CmX00W_O3j2b20UApPsu8OMscNrty9_D0wbgCvDoDNjvbh9LIxfyHkwhSqqZwH04cFVN-RUomu2KYIx9T8d34Mf7fPO_-aeP6OMSi_IOOlLfjIZVoskGTuQHzbU5-Dh6xhM41it--5auB</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Abediazar, S</creator><creator>Nakhjavani, M.R</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Effect of Alendronate on Early Bone Loss of Renal Transplant Recipients</title><author>Abediazar, S ; Nakhjavani, M.R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-ed15a9af0c63c819c78f6c435967be50c95481d8d00b4cad60aa21e713f084d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Alendronate - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Body Mass Index</topic><topic>Bone and Bones - drug effects</topic><topic>Bone Density</topic><topic>Bone Density Conservation Agents - pharmacology</topic><topic>Bone Diseases - complications</topic><topic>Densitometry - methods</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Kidney Transplantation - methods</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osteoporosis. Osteomalacia. Paget disease</topic><topic>Prospective Studies</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tissue, organ and graft immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abediazar, S</creatorcontrib><creatorcontrib>Nakhjavani, M.R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abediazar, S</au><au>Nakhjavani, M.R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Alendronate on Early Bone Loss of Renal Transplant Recipients</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>43</volume><issue>2</issue><spage>565</spage><epage>567</epage><pages>565-567</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Introduction Renal transplant recipients (RTRs) are at risk of developing osteoporosis and osteopenia due to underlying renal osteodystrophy, hypophosphatemia, and immunosuppression. This process occurs more frequently in the first year after renal transplantation (RTX), resulting in eventual bone loss and fractures. The purpose of this study was to evaluate the effect of low-dose alendronate to prevent early bone loss after RTX. Patients and Methods We prospectively studied 43 successful RTR including 22 men and 21-women with a mean overall age of 39.16 ± 11.73 years, mean body mass index of 23.6 ± 3.73, and mean dialysis duration of 25.73 ± 17.67 months. We matched them based on age and sex: the alendronate-treated group received vitamin D (Vit D) during the study plus 30 mg alendronate weekly from 1 month after RTX. The control group only received Vit D. We measured serum calcium, phosphate, alkaline phosphatase, blood urea, creatinine, and intact parathyroid hormone (iPTH) at the pretransplant baseline and monthly thereafter as well as BMD of the lumbar spine, femur, and radius pretransplant baseline versus 3 and 6 months after RTX. Results At 6 month after RTX, the lumbar BMD in the alendronate group increased significantly from 0.819 ± 0.11 to 0.863 ± 0.14 ( P < .01), while it decreased in the control group from 0.897 ± 0.17 to 0.817 ± 0.16 ( P < .001). There was also a significant increase in radius BMD ( P < .001) and a nonsignificant increase in femoral BMD in the alendronate versus a significant decrease of femoral and radius BMD ( P < .001) in the control group at 6 months. Upon multivariate analysis, there was a significant correlation between alendronate and spine BMD ( r = .45, P < .001) but no linear regression between age, sex, BMI, dialysis duration of or iPTH with femoral, spine, or radius BMD changes at month 6. Conclusion Low-dose alendronate was significantly useful to mitigate fast bone loss and increase BMD immediately after RTX.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>21440762</pmid><doi>10.1016/j.transproceed.2011.01.025</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 2011-03, Vol.43 (2), p.565-567 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_859054601 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Alendronate - pharmacology Biological and medical sciences Body Mass Index Bone and Bones - drug effects Bone Density Bone Density Conservation Agents - pharmacology Bone Diseases - complications Densitometry - methods Diseases of the osteoarticular system Female Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Kidney Failure, Chronic - complications Kidney Transplantation - adverse effects Kidney Transplantation - methods Male Medical sciences Middle Aged Osteoporosis. Osteomalacia. Paget disease Prospective Studies Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tissue, organ and graft immunology |
| title | Effect of Alendronate on Early Bone Loss of Renal Transplant Recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T10%3A45%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Alendronate%20on%20Early%20Bone%20Loss%20of%20Renal%20Transplant%20Recipients&rft.jtitle=Transplantation%20proceedings&rft.au=Abediazar,%20S&rft.date=2011-03-01&rft.volume=43&rft.issue=2&rft.spage=565&rft.epage=567&rft.pages=565-567&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2011.01.025&rft_dat=%3Cproquest_cross%3E859054601%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=859054601&rft_id=info:pmid/21440762&rft_els_id=1_s2_0_S0041134511000261&rfr_iscdi=true |